Accelerating Concept to Patients: MilliporeSigma CDMO & Testing Services

​Join MilliporeSigma CDMO specialists for a Lunch & Learn on four of the most in-demand contract development and manufacturing service areas in life sciences today: ADC & Bioconjugation, Lipid & LNP, Viral Vector, and BioReliance Contract Testing.

​Whether you are advancing a next-generation antibody-drug conjugate, developing an mRNA or gene therapy program, or seeking trusted biosafety testing for your regulatory submissions, the full scope of CDMO capabilities shapes your program's speed, quality, and long-term success.

​Learn how early decisions on modality selection, technology transfer, and manufacturing partnerships accelerate timelines, and how integrated multi-site CDMO networks reduce risk from preclinical through commercial scale.

​Enjoy lunch, connect with fellow innovators, and leave with a clearer view of how a world-class CDMO partner moves your therapies from concept to patients.

​What you will take away

• ​End-to-end ADC & Bioconjugation, from linker-payload development to GMP conjugation and fill/finish

• ​Scalable Lipid & LNP formulation, from early screening to clinical and commercial manufacturing

• ​Viral vector development and manufacturing across AAV, lentiviral, and adenoviral platforms

• ​BioReliance Contract Testing for mammalian biosafety, analytical release, and lot release

• ​How an integrated CDMO partnership compresses timelines and reduces program risk

​Who should attend

​Founders, CEOs, CSOs, CMC leaders, and R&D and operations professionals at biotech and biopharma companies advancing biologics, gene therapies, or novel drug delivery programs.